AdvaMed® Submits Comments on Local Coverage Determination of Skin Substitutes
AdvaMed® submitted a letter regarding proposed local coverage determinations entitled “Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcer.”
AdvaMed® Comments on Proposed CDC Clinical Practice Guideline for Prescribing Opioids
AdvaMed® urged CDC to recognize the critical role evidence-based and FDA-approved/cleared devices can and should play in improving pain management and reducing opioid-related harms.
AdvaMed® Statements from Centers for Medicare and Medicaid Services Listening Sessions on Transitional Coverage of Emerging Technologies
During two listening sessions, AdvaMed® provided responses to a set of questions posed by CMS on the parameters for a new TCET program, including the types of guidance provided by…
AdvaMed® Responds to HHS Office of the National Coordinator Request for Information on Electronic Prior Authorization Standards
AdvaMed® submitted a response to a Department of Health and Human Services (HHS) Office of the National Coordinator for Health Information Technology (ONC) Request for Information (RFI) on electronic prior…
AdvaMed® Responds to U.S. House of Representatives Health Futures Task Force, Subcommittee on Treatments Request for Information on Fostering Patient Access to Life-Saving Cures
AdvaMed® submitted a response to a U.S. House of Representatives Healthy Futures Task Force, Subcommittee on Treatments (Subcommittee on Treatments) Request for Information (RFI) on information to help foster patient…
AdvaMed® Advocates for Skin Substitute Coding and Coverage Policy Changes in Advance of Annual Rulemaking
AdvaMed® submitted a letter to the Centers for Medicare and Medicaid Services (CMS) regarding coverage and payment policies for skin substitute products as used and paid for in the outpatient…
AdvaMed® Advocates for Policy Updates in Advance of Annual Rulemaking on End-Stage Renal Disease Payment
In advance of CMS’ release of the proposed End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) rule, AdvaMed® submitted a letter focused on coverage and payment policies for ESRD patients.
AdvaMed® Comments on Advance Notice of Medicare Advantage Capitation Rates and Part C and D Payment Policies
AdvaMed® submitted comments on the Centers for Medicare and Medicaid Services’ Advance Notice of Methodological Changes for Calendar Year 2023 for Medicare Advantage Capitation Rate and Part C and Part…
AdvaMed® Responds to U.S. House of Representatives Health Futures Task Force, Modernization Subcommittee Request for Information on Utilization of Wearable Technologies and Digital Modernization
AdvaMed® submitted a response to a U.S. House of Representatives Healthy Futures Task Force, Modernization Subcommittee (the Modernization Subcommittee) Request for Information (RFI) on the utilization of wearable technologies, expansion…
AdvaMed® Advocates for Policy Updates in Advance of Annual Rulemaking on Physician Payment
AdvaMed® submitted a letter to the Centers for Medicare and Medicaid Services (CMS) regarding coverage and payment policies addressed under the Physician Fee Schedule (PFS) in anticipation of upcoming Calendar…